Ascletis Flaunts Promise Of Its Co-Formulation Of Amylin/GLP-1/GIPR Agonists In Obesity

 
• By Xu Hu
  
Ascletis released promising weight loss data of its amylin receptor and GLP-1/GIPR agonist co-formulation in a rat model, while safety outcomes are currently not disclosed. (Shutterstock)

More from China

More from Focus On Asia